Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 18, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 18, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 239 Common Stock at $509.48 ($121,767) on August 18, 2026; holds 333,704 after (Indirect).
- Open-market sale: disposed of 231 Common Stock at $510.47 ($117,919) on August 18, 2026; holds 333,473 after (Indirect).
- Open-market sale: disposed of 170 Common Stock at $511.59 ($86,971) on August 18, 2026; holds 333,303 after (Indirect).
- Open-market sale: disposed of 439 Common Stock at $513.06 ($225,234) on August 18, 2026; holds 332,864 after (Indirect).
- Open-market sale: disposed of 1,264 Common Stock at $514.18 ($649,918) on August 18, 2026; holds 331,600 after (Indirect).
- Open-market sale: disposed of 2,333 Common Stock at $514.99 ($1,201,464) on August 18, 2026; holds 329,267 after (Indirect).
- Open-market sale: disposed of 1,880 Common Stock at $516.04 ($970,164) on August 18, 2026; holds 327,387 after (Indirect).
- Open-market sale: disposed of 873 Common Stock at $517.09 ($451,419) on August 18, 2026; holds 326,514 after (Indirect).
- Open-market sale: disposed of 1,630 Common Stock at $518.19 ($844,642) on August 18, 2026; holds 324,884 after (Indirect).
- Open-market sale: disposed of 441 Common Stock at $518.65 ($228,724) on August 18, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on August 18, 2026; holds 113,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,898,221 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-08-18 | Open-market sale | Common Stock | 239 | $509 | $121.8K | 333,704 |
| 2026-08-18 | Open-market sale | Common Stock | 231 | $510 | $117.9K | 333,473 |
| 2026-08-18 | Open-market sale | Common Stock | 170 | $512 | $87.0K | 333,303 |
| 2026-08-18 | Open-market sale | Common Stock | 439 | $513 | $225.2K | 332,864 |
| 2026-08-18 | Open-market sale | Common Stock | 1,264 | $514 | $649.9K | 331,600 |
| 2026-08-18 | Open-market sale | Common Stock | 2,333 | $515 | $1.2M | 329,267 |
| 2026-08-18 | Open-market sale | Common Stock | 1,880 | $516 | $970.2K | 327,387 |
| 2026-08-18 | Open-market sale | Common Stock | 873 | $517 | $451.4K | 326,514 |
| 2026-08-18 | Open-market sale | Common Stock | 1,630 | $518 | $844.6K | 324,884 |
| 2026-08-18 | Open-market sale | Common Stock | 441 | $519 | $228.7K | 324,443 |
| 2026-08-18 | Option exercise/conversion | Stock Option | 9,500 | — | — | 113,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Option exercise/conversion (9,500 shares) |
| 2026-08-18 | Open-market sale (239 shares) |
| 2026-08-18 | Open-market sale (231 shares) |
| 2026-08-18 | Open-market sale (170 shares) |
| 2026-08-18 | Open-market sale (439 shares) |
| 2026-08-18 | Open-market sale (1,264 shares) |
| 2026-08-18 | Open-market sale (2,333 shares) |
| 2026-08-18 | Open-market sale (1,880 shares) |
| 2026-08-18 | Open-market sale (873 shares) |
| 2026-08-18 | Open-market sale (1,630 shares) |
| 2026-08-18 | Open-market sale (441 shares) |
| 2026-08-18 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.